[Optimization of treatment focal forms of epilepsy in young children].
A clinical trial included 30 children, aged from 24 to 46 months, stratified into two groups on the basis of clinical-instrumental data: 22 (73%) patients with symptomatic focal epilepsy and 8 (27%) patients with cryptogenic (possibly symptomatic) focal epilepsy. Topamax (topiramate) was used as mono- (8 children) and combined (22 children) therapy. Mean treatment dose was 5,9 mg/kg per day. Efficacy of treatment was evaluated by the changes in frequency of seizures. After 6 months, the positive result (completed stopping of seizures or their reduction by 50% and more) was seen in 19 (63,75%) patients. The effect was absent or was minimal in 9 (29,5%). In 2 (6,75%) cases the frequency of seizures increased. Adverse events were recorded in 11 (36%) patients, side-effects that led to the treatment discontinuation (vomiting, increasing of seizure frequency, enuresis) were found in 5 (16%) patients.